REGENXBIO to Showcase Gene Therapy Advances at 2026 ASGCT Annual Meeting in Boston
- REGENXBIO will showcase advancements in gene therapy, particularly the RGX-202 program for Duchenne muscular dystrophy (DMD) at ASGCT 2026.
- Dr. Aravindhan Veerapandiyan will present key findings from RGX-202, enhancing discussions on in vivo clinical trials for muscular disorders.
- REGENXBIO's presentations highlight its commitment to innovation and leadership in biotechnology, focusing on effective gene therapy solutions.
REGENXBIO Inc. is set to highlight its advancements in gene therapy at the upcoming 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place from May 11-15 in Boston, Massachusetts. This notable event serves as a platform for the company to showcase its significant progress in gene therapy treatments, particularly through its RGX-202 program targeted at Duchenne muscular dystrophy (DMD). Dr. Metewo Selase Kosi Enuameh is slated to discuss innovations in the NAVXpress® manufacturing platform, emphasizing improvements in production efficiency and product quality, which are critical for delivering effective therapies to patients. The spotlight on RGX-202 as part of the presentations underscores REGENXBIO's commitment to addressing genetic disorders with cutting-edge solutions.
Additionally, Dr. Aravindhan Veerapandiyan will present pivotal findings from the RGX-202 program, enriching the dialogue about in vivo clinical trials for muscular disorders. This aspect of the conference reflects REGENXBIO's dedication to advancing medical treatments for rare diseases. Alongside oral presentations, the company will also share a series of insightful poster presentations that delve into innovative topics such as NVG82, a specialized capsid engineered for improved retinal gene transfer, as well as detailed analyses of various transduction routes in rodent models. These presentations illustrate not just REGENXBIO's passion for innovation but also its success in AAV gene therapy, which has benefited many patients.
The ASGCT Annual Meeting emphasizes REGENXBIO’s leadership in developing transformative gene therapies, further solidifying its role in the biotechnology landscape. By addressing critical health challenges and presenting at such a prestigious forum, REGENXBIO demonstrates its ongoing commitment to innovation and excellence in treatment for high-need patient populations. Through its focused research and high-quality presentations, the company positions itself as a leader in the fast-evolving field of gene therapy, continuously pushing the frontiers of what is possible in biotechnology.